User profiles for "author:Cesar Magro-Checa"

César Magro-Checa

Rheumatologist, Zuyderland Medical Center
Verified email at zuyderland.nl
Cited by 2467

[HTML][HTML] Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives

C Magro-Checa, EJ Zirkzee, TW Huizinga… - Drugs, 2016 - Springer
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a generic definition referring to a
series of neurological and psychiatric symptoms directly related to systemic lupus …

Calcium pyrophosphate crystal deposition disease: diagnosis and treatment

JL Rosales-Alexander, J Balsalobre Aznar… - … research and reviews, 2014 - Taylor & Francis
Calcium pyrophosphate dihydrate crystal deposition disease (CPPD) is an inflammatory
arthritis produced by the deposition of calcium pyrophosphate (CPP) crystals in the …

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm …

S Ramiro, RLM Mostard, C Magro-Checa… - Annals of the …, 2020 - ard.bmj.com
Objectives To prospectively investigate in patients with severe COVID-19-associated
cytokine storm syndrome (CSS) whether an intensive course of glucocorticoids with or …

[HTML][HTML] Laboratory and neuroimaging biomarkers in neuropsychiatric systemic lupus erythematosus: where do we stand, where to go?

C Magro-Checa, GM Steup-Beekman… - Frontiers in …, 2018 - frontiersin.org
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by
multi-systemic involvement. Nervous system involvement in SLE leads to a series of …

EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19

A Alunno, A Najm, PM Machado… - Annals of the …, 2021 - ard.bmj.com
Objectives Severe systemic inflammation associated with some stages of COVID-19 and in
fatal cases led therapeutic agents developed or used frequently in Rheumatology being at …

Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites

E Ercan, C Magro-Checa, R Valabregue, F Branzoli… - Brain, 2016 - academic.oup.com
Systemic lupus erythematosus is an inflammatory autoimmune disease with multi-organ
involvement. Central nervous system involvement in systemic lupus erythematosus is …

2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

A Alunno, A Najm, PM Machado… - Annals of the …, 2022 - ard.bmj.com
Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort

C Magro-Checa, EJ Zirkzee… - …, 2017 - academic.oup.com
Objective To determine the contribution of reassessment in the attribution process of
neuropsychiatric (NP) events to SLE or other aetiologies in a large, prospective and …

[HTML][HTML] Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts

M Ziegelasch, MAM van Delft, P Wallin, T Skogh… - Arthritis research & …, 2016 - Springer
Background Articular manifestations are common in systemic lupus erythematosus (SLE)
whereas erosive disease is not. Antibodies to cyclic citrullinated peptide (anti-CCP) are …

[HTML][HTML] Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer

RJH Martens, AJ van Adrichem… - Clinical Chemistry and …, 2021 - degruyter.com
Objectives COVID-19 is an ongoing global pandemic. There is an urgent need for
identification and understanding of clinical and laboratory parameters related to progression …